MedTrace Logo

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

NCT04420988 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-11-28

No results posted yet for this study

Summary

This is an expanded access program providing COVID-19 convalescent plasma to patients hospitalized with severely or life-threateningly ill COVID-19.

Conditions

  • COVID-19
  • SARS-CoV 2
  • SARS-CoV Infection

Interventions

BIOLOGICAL

COVID-19 Convalescent Plasma

COVID-19 Convalescent Plasma from recovered COVID-19 patients transfusion into severely or life-threateningly ill COVID-19 infected patients

Sponsors & Collaborators

  • University Hospital - Newark, NJ

    collaborator UNKNOWN

  • Rutgers, The State University of New Jersey

    lead OTHER

Principal Investigators

  • Marc Klapholz, MD, MBA · Rutgers New Jersey Medical School; University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420988 on ClinicalTrials.gov